1 / 16

Self-Sufficiency of Plasma Derivatives

Self-Sufficiency of Plasma Derivatives. Definition. The provision of human blood and plasma products from within a certain population to satisfy the clinical needs of that population. History & Rationale. Council of Europe. Recommendation R (88) 4, March 1988 :

keenan
Télécharger la présentation

Self-Sufficiency of Plasma Derivatives

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Self-Sufficiency of Plasma Derivatives

  2. Definition • The provision of human blood and plasma products from within a certain population to satisfy the clinical needs of that population

  3. History & Rationale • Council of Europe. Recommendation R (88) 4, March 1988 : • Every country should aim at self-sufficiency in the supply and distribution of blood over its entire territory • “ Self-sufficiency with respect to blood products is one of the basic conditions for minimising the hazard of the transmission of infectious disease by blood transfusion”

  4. Other Advantages • Improved utilisation of national resources • Prevention of “virus tourism” • Represents relevant local antibody content • Cost reduction opportunity • Increased availability of products • Equality of treatment • Avoids introduction of sub-optimal products

  5. Prerequisites • National commitment • Selection of a fractionation partner with experience in the development, administration and logistics of self-sufficiency projects

  6. Attaining Self-Sufficiency • Degree & cost-savings of self-sufficiency based on: • Careful selection of fractionation partner • Safe & reliable project administration • Variable and small batch sizes • Safe, reliable and consistent production • State-of-the-art products • High yields

  7. Selection of Fractionation Partner • Proven experience of managing self-sufficiency projects • Fractionation capacity • International & local reputation • Solid financial background • Reliable local representation

  8. Safe & Reliable Project Administration • Established history of self-sufficiency ability • “Total package” administration: • Donor centre auditing donor recruitment programmes • Educational support staff training • Distribution transportation logistics • Trust & transparency • Pro-active problem-solving approach • Ongoing commitment to evaluation & improvement

  9. Variable Production Scales • Ability to offer both regional and national self-sufficiency requires: • Production flexibility • Variable batch size • Short production & delivery schedules • Commitment to safety

  10. Safe, Reliable, Consistent Production • GMP: Good Manufacturing Practice • Batch-to-batch consistency • Attainment & maintenance of international standards • Independent batch release by recognised international laboratories

  11. State-of-the-Art Products • Worldwide registrations • Double virus inactivation • Purification methods • Ongoing R&D programme • Product / portfolio enhancement option included in contract

  12. High Yields • Maximum utilisation of valuable national resource • Increased availability of products • More patients access treatment • Expansion of clinical indications • Improved treatment regimens • Prophylaxis • Immune tolerance • Surgical procedures • Optimised costs

  13. State-of-the-Art Facilities • Separation of product, material, personnel and waste flows • Validation of processes, analytical methods and equipment • Clean areas according to the production steps • Training of the employees • Efficient technology

  14. Dedicated to Self-Sufficiency • Size of the fractionation batches • Dedicated equipment according to plasma origin • Fractionation equipment with CIP and SIP • Autonomy for the whole process, from plasma to final product

  15. Octapharma & Self-Sufficiency • Octapharma products have significantly improved the quality of life for thousands of patients in Norway during the last 15 years • Around 200 haemophiliacs are treated with Octapharma products every year • Waiting-lists for elective surgery in haemophiliacs have disappeared • The haemophilia treatment regimen has now reached a level of high European standard • Emergency stock of plasma products increased from zero to six months • Flesland O et al. The Norwegian plasma fractionation project: A 12 year clinical & economic success story. Transfusion & Apheresis Science 2003; 28: 93-100

  16. Octapharma Self-Sufficiency Experience • More than 15 years experience with self-sufficiency programmes • Austria • Belgium • Brazil • Germany • Norway • Slovenia • France • Netherlands, etc

More Related